Literature DB >> 11151397

Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

I Côté1, J P Grégoire, J Moisan.   

Abstract

In hypertension, tolerability of drug treatment is important because individuals may see the use of antihypertensive medications as more troubling than their seemingly symptomless disease. This may result in noncompliance and ineffectual long term treatment. In the past 15 years, new antihypertensive medications have been marketed on the basis of the advantages they offer with regard to adverse effects and the unavoidable impact of such adverse effects on a person's quality of life. When related to health, quality of life refers to the physical, psychological and social dimensions of health that are influenced by a person's experiences, beliefs, expectations and perceptions. To measure this concept, many instruments, either generic or specific, may be used. The purpose of this study is to describe, by way of a critical review of the literature, the instruments that are most often used in the measurement of health-related quality of life (HR-QOL) in people using antihypertensive drug treatments. We carried out a search of the literature published in English in the period January 1966 to July 2000, looking for randomised controlled trials of antihypertensive drugs. Using the Medline database, we included 77 papers in our review. Our main finding suggests that HR-QOL changes associated with antihypertensive treatment are measured with many different instruments. In almost all studies, at least 1 instrument specific to a health dimension was used, whereas not many used a generic instrument only. The most commonly measured HR-QOL dimensions were cognitive function, symptomatic well-being, sexual function, psychological well-being, sleep dysfunction, social participation and general health perception. Since the choice of dimensions to measure depends not only on the disease but also on the drug, this review adds further evidence that a generic instrument as well as a preference measurement should be added to a specific instrument.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11151397     DOI: 10.2165/00019053-200018050-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  100 in total

Review 1.  Quality of life in cystic fibrosis.

Authors:  D E Tullis; G H Guyatt
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

2.  Efficacy and influence on quality of life of enalapril as a first step treatment of hypertension.

Authors:  G Chatellier; P Sassano; A M Amiot; P Corvol; J Ménard
Journal:  Clin Exp Hypertens A       Date:  1987

3.  Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black Hypertension Quality of Life Multicenter Trial Group.

Authors:  S H Croog; B W Kong; S Levine; M R Weir; R M Baume; E Saunders
Journal:  Arch Intern Med       Date:  1990-08

4.  Comparison of enalapril and atenolol in mild to moderate hypertension.

Authors:  A L Herrick; P C Waller; K E Berkin; S D Pringle; J S Callender; M P Robertson; J G Findlay; G D Murray; J L Reid; A R Lorimer
Journal:  Am J Med       Date:  1989-04       Impact factor: 4.965

5.  The effects of verapamil and propranolol on quality of life in hypertension.

Authors:  A E Fletcher; P C Chester; C M Hawkins; A N Latham; L A Pike; C J Bulpitt
Journal:  J Hum Hypertens       Date:  1989-04       Impact factor: 3.012

6.  Effects of antihypertensive medications on vitality and well-being.

Authors:  S Levine; S H Croog; A Sudilovsky; M A Testa
Journal:  J Fam Pract       Date:  1987-10       Impact factor: 0.493

7.  Disparate effects of initial antihypertensive therapy on well-being.

Authors:  H Otten; R Schmeider; H Rüddel
Journal:  J Hypertens Suppl       Date:  1987-02

8.  Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients.

Authors:  E McCorvey; J T Wright; J P Culbert; J M McKenney; J D Proctor; M P Annett
Journal:  Clin Pharm       Date:  1993-04

9.  Hypertension in the elderly: 24 h ambulatory blood pressure results from a placebo-controlled trial.

Authors:  J M Neutel; D H Smith; M P Lefkowitz; P Cargo; D Alemayehu; M A Weber
Journal:  J Hum Hypertens       Date:  1995-09       Impact factor: 3.012

10.  Health related utility measurement: an introduction.

Authors:  C Bakker; S van der Linden
Journal:  J Rheumatol       Date:  1995-06       Impact factor: 4.666

View more
  5 in total

Review 1.  Are all outcomes in chronic heart failure rated equally? An argument for a patient-centred approach to outcome assessment.

Authors:  Sungwon Chang; Phillip J Newton; Sally Inglis; Tim Luckett; Henry Krum; Peter Macdonald; Patricia M Davidson
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 2.  Health-related quality of life in hypertension, chronic kidney disease, and coexistent chronic health conditions.

Authors:  Ritu K Soni; Anna C Porter; James P Lash; Mark L Unruh
Journal:  Adv Chronic Kidney Dis       Date:  2010-07       Impact factor: 3.620

3.  Systolic blood pressure and subjective well-being in patients with coronary artery disease.

Authors:  Yan Gong; Eileen M Handberg; Tobias Gerhard; Rhonda M Cooper-Dehoff; L Douglas Ried; Julie A Johnson; Carl J Pepine
Journal:  Clin Cardiol       Date:  2009-11       Impact factor: 2.882

4.  Functional outcomes of multi-condition collaborative care and successful ageing: results of randomised trial.

Authors:  Michael Von Korff; Wayne J Katon; Elizabeth H B Lin; Paul Ciechanowski; Do Peterson; Evette J Ludman; Bessie Young; Carolyn M Rutter
Journal:  BMJ       Date:  2011-11-10

5.  An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).

Authors:  Setareh A Williams; Eric L Michelson; Valerie A Cain; Min Yang; Shawna D Nesbitt; Brent M Egan; Stevo Julius
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-06       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.